Koda Yusuke, Ome Yusuke, Okita Chika, Kawamoto Kazuyuki
Dept. of Gastroenterological Surgery, Takamatsu Red Cross Hospital.
Gan To Kagaku Ryoho. 2018 Dec;45(12):1759-1761.
A 66-year-old man was admitted to undergo investigation for body weight loss. He was diagnosed with pancreatic neuroendocrine carcinoma, and a pancreaticoduodenectomy was performed. Three months after surgery, multiple recurrent liver metastases were observed on CT. We administered the cisplatin(CDDP)/irinotecan(CPT-11)regimen, but decided to discontinue the regimen because of adverse events. One month later, administration of everolimus(10mg/day)was initiated. Lesion loss was observed after 8 months, and the patient achieved a complete response(CR)without abnormal accumulation of FDG on PET-CT. Administration of everolimus was discontinued after 13 months because of peripheral neuropathy. Despite drug withdrawal, the patient has remained in remission for more than 3 years. Everolimus is considered an effective treatment for MANEC from NEC.
一名66岁男性因体重减轻入院接受检查。他被诊断为胰腺神经内分泌癌,并接受了胰十二指肠切除术。术后三个月,CT检查发现多处复发性肝转移。我们给予顺铂(CDDP)/伊立替康(CPT-11)方案,但由于不良事件决定停用该方案。一个月后,开始服用依维莫司(10mg/天)。8个月后观察到病灶缩小,患者达到完全缓解(CR),PET-CT上未出现FDG异常聚集。13个月后因周围神经病变停用依维莫司。尽管停药,但患者已缓解超过3年。依维莫司被认为是治疗神经内分泌癌来源的混合性神经内分泌-非神经内分泌癌的有效药物。